{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:33:36Z","timestamp":1774384416644,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Bethune Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02122-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:57:22Z","timestamp":1773910642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia"],"prefix":"10.1007","volume":"26","author":[{"given":"Jie","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-1235","authenticated-orcid":false,"given":"Fujue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"2","key":"2122_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.seminhematol.2018.08.001","volume":"56","author":"SF Cai","year":"2019","unstructured":"Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56(2):84\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.08.001.","journal-title":"Semin Hematol"},{"issue":"14","key":"2122_CR2","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.7150\/jca.42093","volume":"11","author":"J Gao","year":"2020","unstructured":"Gao J, Wang F, Wu P, Chen Y, Jia Y. Aberrant LncRNA Expression in Leukemia. J Cancer. 2020;11(14):4284\u201396. https:\/\/doi.org\/10.7150\/jca.42093.","journal-title":"J Cancer"},{"issue":"2","key":"2122_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308\u201320. https:\/\/doi.org\/10.3324\/haematol.2022.280801.","journal-title":"Haematologica"},{"issue":"12","key":"2122_CR4","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795\u2013804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8.","journal-title":"Leukemia"},{"issue":"2","key":"2122_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41571-018-0156-2","volume":"16","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Perl AE. Advances in patient care through increasingly individualized therapy. Nat reviews Clin Oncol. 2019;16(2):73\u20134. https:\/\/doi.org\/10.1038\/s41571-018-0156-2.","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"2122_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F. Acute myeloid leukemia management and research in 2025. Cancer J Clin. 2025;75(1):46\u201367. https:\/\/doi.org\/10.3322\/caac.21873.","journal-title":"Cancer J Clin"},{"issue":"1","key":"2122_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, Kadia T, Sasaki K, Short NJ, Yilmaz M, Ravandi F. Current status and research directions in acute myeloid leukemia. Blood cancer J. 2024;14(1):163. https:\/\/doi.org\/10.1038\/s41408-024-01143-2.","journal-title":"Blood cancer J"},{"issue":"12","key":"2122_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145(12):1237\u201350. https:\/\/doi.org\/10.1182\/blood.2024024009.","journal-title":"Blood"},{"key":"2122_CR9","doi-asserted-by":"publisher","unstructured":"Inoue Y, Cioccio J, Mineishi S, Minagawa K. Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML. Cells. 2025;14(8). https:\/\/doi.org\/10.3390\/cells14080572.","DOI":"10.3390\/cells14080572"},{"key":"2122_CR10","doi-asserted-by":"publisher","unstructured":"Pei X, Huang X. (2019) New approaches in allogenic transplantation in AML. Seminars in hematology 56 (2):147\u201354. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.08.007","DOI":"10.1053\/j.seminhematol.2018.08.007"},{"issue":"5","key":"2122_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025;100(5):860\u201391. https:\/\/doi.org\/10.1002\/ajh.27625.","journal-title":"Am J Hematol"},{"issue":"1\u20132","key":"2122_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000015131","volume":"83","author":"SD Pack","year":"1998","unstructured":"Pack SD, Pak E, Tanigami A, Ledbetter DH, Fukuda MN. Assignment1 of the bystin gene BYSL to human chromosome band 6p21.1 by in situ hybridization. Cytogenet Cell Genet. 1998;83(1\u20132):76\u20137. https:\/\/doi.org\/10.1159\/000015131.","journal-title":"Cytogenet Cell Genet"},{"issue":"23","key":"2122_CR13","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.1158\/1078-0432.ccr-05-1028","volume":"11","author":"Y Kasugai","year":"2005","unstructured":"Kasugai Y, Tagawa H, Kameoka Y, Morishima Y, Nakamura S, Seto M. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin cancer research: official J Am Association Cancer Res. 2005;11(23):8265\u201372. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-1028.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"3","key":"2122_CR14","first-page":"247","volume":"64","author":"MN Fukuda","year":"2012","unstructured":"Fukuda MN, Sugihara K. Cell adhesion molecules in human embryo implantation. Sheng Li Xue Bao. 2012;64(3):247\u201358.","journal-title":"Sheng Li Xue Bao"},{"issue":"3","key":"2122_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/s-2000-12564","volume":"18","author":"R Aoki","year":"2000","unstructured":"Aoki R, Fukuda MN. Recent molecular approaches to elucidate the mechanism of embryo implantation: trophinin, bystin, and tastin as molecules involved in the initial attachment of blastocysts to the uterus in humans. Semin Reprod Med. 2000;18(3):265\u201371. https:\/\/doi.org\/10.1055\/s-2000-12564.","journal-title":"Semin Reprod Med"},{"issue":"3","key":"2122_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-2007-1016230","volume":"17","author":"MN Fukuda","year":"1999","unstructured":"Fukuda MN, Nozawa S. Trophinin, tastin, and bystin: a complex mediating unique attachment between trophoblastic and endometrial epithelial cells at their respective apical cell membranes. Seminars reproductive Endocrinol. 1999;17(3):229\u201334. https:\/\/doi.org\/10.1055\/s-2007-1016230.","journal-title":"Seminars reproductive Endocrinol"},{"issue":"6","key":"2122_CR17","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1128\/mcb.01908-06","volume":"27","author":"K Adachi","year":"2007","unstructured":"Adachi K, Soeta-Saneyoshi C, Sagara H, Iwakura Y. Crucial role of Bysl in mammalian preimplantation development as an integral factor for 40S ribosome biogenesis. Mol Cell Biol. 2007;27(6):2202\u201314. https:\/\/doi.org\/10.1128\/mcb.01908-06.","journal-title":"Mol Cell Biol"},{"issue":"7709","key":"2122_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-018-0193-0","volume":"558","author":"M Ameismeier","year":"2018","unstructured":"Ameismeier M, Cheng J, Berninghausen O, Beckmann R. Visualizing late states of human 40S ribosomal subunit maturation. Nature. 2018;558(7709):249\u201353. https:\/\/doi.org\/10.1038\/s41586-018-0193-0.","journal-title":"Nature"},{"issue":"1","key":"2122_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12024-017-9942-x","volume":"14","author":"M Olczak","year":"2018","unstructured":"Olczak M, Chutora\u0144ski D, Kwiatkowska M, Samoj\u0142owicz D, Tarka S, Wierzba-Bobrowicz T. Bystin (BYSL) as a possible marker of severe hypoxic-ischemic changes in neuropathological examination of forensic cases. Forensic Sci Med Pathol. 2018;14(1):26\u201330. https:\/\/doi.org\/10.1007\/s12024-017-9942-x.","journal-title":"Forensic Sci Med Pathol"},{"issue":"4","key":"2122_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1460-9568.2004.03567.x","volume":"20","author":"J Sheng","year":"2004","unstructured":"Sheng J, Yang S, Xu L, Wu C, Wu X, Li A, Yu Y, Ni H, Fukuda M, Zhou J. Bystin as a novel marker for reactive astrocytes in the adult rat brain following injury. Eur J Neurosci. 2004;20(4):873\u201384. https:\/\/doi.org\/10.1111\/j.1460-9568.2004.03567.x.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"2122_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/bj20061597","volume":"404","author":"M Miyoshi","year":"2007","unstructured":"Miyoshi M, Okajima T, Matsuda T, Fukuda MN, Nadano D. Bystin in human cancer cells: intracellular localization and function in ribosome biogenesis. Biochem J. 2007;404(3):373\u201381. https:\/\/doi.org\/10.1042\/bj20061597.","journal-title":"Biochem J"},{"issue":"10","key":"2122_CR22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/cr.2009.99","volume":"19","author":"H Wang","year":"2009","unstructured":"Wang H, Xiao W, Zhou Q, Chen Y, Yang S, Sheng J, Yin Y, Fan J, Zhou J. Bystin-like protein is upregulated in hepatocellular carcinoma and required for nucleologenesis in cancer cell proliferation. Cell Res. 2009;19(10):1150\u201364. https:\/\/doi.org\/10.1038\/cr.2009.99.","journal-title":"Cell Res"},{"issue":"3","key":"2122_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/pros.20323","volume":"66","author":"GE Ayala","year":"2006","unstructured":"Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM. Bystin in perineural invasion of prostate cancer. Prostate. 2006;66(3):266\u201372. https:\/\/doi.org\/10.1002\/pros.20323.","journal-title":"Prostate"},{"issue":"1","key":"2122_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.20892\/j.issn.2095-3941.2020.0096","volume":"18","author":"S Gao","year":"2021","unstructured":"Gao S, Sha Z, Zhou J, Wu Y, Song Y, Li C, Liu X, Zhang T, Yu R. BYSL contributes to tumor growth by cooperating with the mTORC2 complex in gliomas. Cancer biology Med. 2021;18(1):88\u2013104. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0096.","journal-title":"Cancer biology Med"},{"key":"2122_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-015-0215-4","volume":"8","author":"GS Laszlo","year":"2015","unstructured":"Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of myocyte enhancer factor 2\u00a0C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. J Hematol Oncol. 2015;8:115. https:\/\/doi.org\/10.1186\/s13045-015-0215-4.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2122_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.molcel.2021.04.014","volume":"81","author":"SS Riedel","year":"2021","unstructured":"Riedel SS, Lu C, Xie HM, Nestler K, Vermunt MW, Lenard A, Bennett L, Speck NA, Hanamura I, Lessard JA, Blobel GA, Garcia BA, Bernt KM. Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. Mol Cell. 2021;81(11):2332\u2013e23482339. https:\/\/doi.org\/10.1016\/j.molcel.2021.04.014.","journal-title":"Mol Cell"},{"issue":"6","key":"2122_CR27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, Verga JA, Stephansky J, Pastika TJ, Lombardi Story J, Pinkus GS, Pozdnyakova O, Galinsky I, Stone RM, Graubert TA, Shalek AK, Aster JC, Lane AA, Bernstein BE. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176(6):1265\u2013e12811224. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031.","journal-title":"Cell"},{"issue":"7","key":"2122_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood.2018888255","volume":"134","author":"T Hu","year":"2019","unstructured":"Hu T, Morita K, Hill MC, Jiang Y, Kitano A, Saito Y, Wang F, Mao X, Hoegenauer KA, Morishita K, Martin JF, Futreal PA, Takahashi K, Nakada D. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells. Blood. 2019;134(7):614\u201325. https:\/\/doi.org\/10.1182\/blood.2018888255.","journal-title":"Blood"},{"key":"2122_CR29","doi-asserted-by":"publisher","first-page":"109643","DOI":"10.1016\/j.cellsig.2020.109643","volume":"72","author":"F Wang","year":"2020","unstructured":"Wang F, Wu P, Gong S, Chen Y, Gao J, Wang S, Shen Q, Tao H, Hua F, Zhou Z, Zou Z, Ma T, Jia Y. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT\/GLI1\/Cyclin D1 pathway. Cell Signal. 2020;72:109643. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109643.","journal-title":"Cell Signal"},{"issue":"4","key":"2122_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"3","key":"2122_CR31","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr2100","volume":"10","author":"EM Azzato","year":"2008","unstructured":"Azzato EM, Driver KE, Lesueur F, Shah M, Greenberg D, Easton DF, Teschendorff AE, Caldas C, Caporaso NE, Pharoah PD. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast cancer research: BCR. 2008;10(3):R47. https:\/\/doi.org\/10.1186\/bcr2100.","journal-title":"Breast cancer research: BCR"},{"key":"2122_CR32","doi-asserted-by":"publisher","first-page":"565225","DOI":"10.3389\/fonc.2020.565225","volume":"10","author":"Z Sha","year":"2020","unstructured":"Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R, Gao S. BYSL Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the GSK-3\u03b2\/\u03b2-Catenin Signaling Pathway. Front Oncol. 2020;10:565225. https:\/\/doi.org\/10.3389\/fonc.2020.565225.","journal-title":"Front Oncol"},{"issue":"16","key":"2122_CR33","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1182\/blood-2009-10-178129","volume":"115","author":"A Narla","year":"2010","unstructured":"Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115(16):3196\u2013205. https:\/\/doi.org\/10.1182\/blood-2009-10-178129.","journal-title":"Blood"},{"issue":"1","key":"2122_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","volume":"8","author":"L Jiao","year":"2023","unstructured":"Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduct Target therapy. 2023;8(1):15. https:\/\/doi.org\/10.1038\/s41392-022-01285-4.","journal-title":"Signal Transduct Target therapy"},{"issue":"11","key":"2122_CR35","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood.2019000947","volume":"136","author":"L Da Costa","year":"2020","unstructured":"Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood. 2020;136(11):1262\u201373. https:\/\/doi.org\/10.1182\/blood.2019000947.","journal-title":"Blood"},{"issue":"7","key":"2122_CR36","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood-2009-06-229443","volume":"115","author":"MG Kharas","year":"2010","unstructured":"Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010;115(7):1406\u201315. https:\/\/doi.org\/10.1182\/blood-2009-06-229443.","journal-title":"Blood"},{"issue":"2","key":"2122_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bbadis.2016.11.013","volume":"1863","author":"FM Roversi","year":"2017","unstructured":"Roversi FM, Pericole FV, Machado-Neto JA, da Silva Santos Duarte A, Longhini AL, Corrocher FA, Palodetto B, Ferro KP, Rosa RG, Baratti MO, Verjovski-Almeida S, Traina F, Molinari A, Botta M, Saad ST. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin\/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin\/PI3K pathway. Biochim et Biophys acta Mol basis disease. 2017;1863(2):450\u201361. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.013.","journal-title":"Biochim et Biophys acta Mol basis disease"},{"issue":"1","key":"2122_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevi\u0107 S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18(1):51\u201363. https:\/\/doi.org\/10.1038\/nrc.2017.104.","journal-title":"Nat Rev Cancer"},{"key":"2122_CR39","doi-asserted-by":"publisher","unstructured":"Carotenuto P, Pecoraro A, Palma G, Russo G, Russo A. Therapeutic Approaches Targeting Nucleolus in Cancer. Cells. 2019;8(9). https:\/\/doi.org\/10.3390\/cells8091090.","DOI":"10.3390\/cells8091090"},{"issue":"21","key":"2122_CR40","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2016-05-718171","volume":"129","author":"N Hein","year":"2017","unstructured":"Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood. 2017;129(21):2882\u201395. https:\/\/doi.org\/10.1182\/blood-2016-05-718171.","journal-title":"Blood"},{"issue":"10","key":"2122_CR41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood.2024026113","volume":"146","author":"A Damaskou","year":"2025","unstructured":"Damaskou A, Wilson R, Gozdecka M, Giotopoulos G, Asby R, Eleftheriou M, Gu M, R\u00e9cher C, Mansat-De Mas V, Vergez F, Sahal A, Vick B, Papachristou EK, Sawle A, Yankova E, Dudek M, Liu X, Russell J, Rak J, Hilcenko C, D\u2019Santos C, Jeremias I, Sarry JE, Tzelepis K, Huntly BJP, Warren AJ, Tavana O, Vassiliou GS. Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML. Blood. 2025;146(10):1239\u201352. https:\/\/doi.org\/10.1182\/blood.2024026113.","journal-title":"Blood"},{"issue":"5","key":"2122_CR42","first-page":"1602","volume":"5","author":"P Xia","year":"2015","unstructured":"Xia P, Xu XY. PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J cancer Res. 2015;5(5):1602\u20139.","journal-title":"Am J cancer Res"},{"key":"2122_CR43","doi-asserted-by":"publisher","unstructured":"Miricescu D, Totan A, Stanescu S, Badoiu II, Stefani SC, Greabu C M. PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020;22(1). https:\/\/doi.org\/10.3390\/ijms22010173.","DOI":"10.3390\/ijms22010173"},{"key":"2122_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","volume":"59","author":"Q Yang","year":"2019","unstructured":"Yang Q, Jiang W, Hou P. Emerging role of PI3K\/AKT in tumor-related epigenetic regulation. Sem Cancer Biol. 2019;59:112\u201324. https:\/\/doi.org\/10.1016\/j.semcancer.2019.04.001.","journal-title":"Sem Cancer Biol"},{"key":"2122_CR45","doi-asserted-by":"publisher","first-page":"107300","DOI":"10.1016\/j.phrs.2024.107300","volume":"206","author":"N Guo","year":"2024","unstructured":"Guo N, Wang X, Xu M, Bai J, Yu H, Le Z. PI3K\/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression. Pharmacol Res. 2024;206:107300. https:\/\/doi.org\/10.1016\/j.phrs.2024.107300.","journal-title":"Pharmacol Res"},{"key":"2122_CR46","doi-asserted-by":"publisher","unstructured":"Nepstad I, Hatfield KJ, Tvedt THA, Reikvam H, Bruserud \u00d8. Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. Cancers. 2018;10(9). https:\/\/doi.org\/10.3390\/cancers10090332.","DOI":"10.3390\/cancers10090332"},{"key":"2122_CR47","doi-asserted-by":"publisher","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int J Mol Sci. 2020;21(8). https:\/\/doi.org\/10.3390\/ijms21082907.","DOI":"10.3390\/ijms21082907"},{"issue":"1","key":"2122_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"issue":"1","key":"2122_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target therapy. 2021;6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Target therapy"},{"key":"2122_CR50","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.yexmp.2022.104787","volume":"127","author":"MR Khezri","year":"2022","unstructured":"Khezri MR, Jafari R, Yousefi K, Zolbanin NM. The PI3K\/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol. 2022;127:104787. https:\/\/doi.org\/10.1016\/j.yexmp.2022.104787.","journal-title":"Exp Mol Pathol"},{"key":"2122_CR51","doi-asserted-by":"publisher","unstructured":"Darici S, Alkhaldi H, Horne G, J\u00f8rgensen HG, Marmiroli S, Huang X. Targeting PI3K\/Akt\/mTOR in AML: Rationale and Clinical Evidence. J Clin Med. 2020;9(9). https:\/\/doi.org\/10.3390\/jcm9092934.","DOI":"10.3390\/jcm9092934"},{"issue":"4","key":"2122_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41389-018-0044-8","volume":"7","author":"A Bastide","year":"2018","unstructured":"Bastide A, David A. The ribosome, (slow) beating heart of cancer (stem) cell. Oncogenesis. 2018;7(4):34. https:\/\/doi.org\/10.1038\/s41389-018-0044-8.","journal-title":"Oncogenesis"},{"issue":"1","key":"2122_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","volume":"60","author":"M Ohanian","year":"2019","unstructured":"Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-Gonz\u00e1lez GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019;60(1):37\u201348. https:\/\/doi.org\/10.1080\/10428194.2018.1464158.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2122_CR54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/2643-3230.Bcd-20-0230","volume":"2","author":"X Wu","year":"2021","unstructured":"Wu X, Eisenman RN. MYC and TFEB Control DNA Methylation and Differentiation in AML. Blood cancer discovery. 2021;2(2):116\u20138. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-20-0230.","journal-title":"Blood cancer discovery"},{"issue":"4","key":"2122_CR55","first-page":"202","volume":"47","author":"R Tang","year":"2021","unstructured":"Tang R, Cheng A, Guirales F, Yeh W, Tirado CA. c-MYC Amplification in AML. J Association Genetic Technol. 2021;47(4):202\u201312.","journal-title":"J Association Genetic Technol"},{"key":"2122_CR56","doi-asserted-by":"publisher","unstructured":"Pippa R, Odero MD. The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias. Cells. 2020;9(3). https:\/\/doi.org\/10.3390\/cells9030544.","DOI":"10.3390\/cells9030544"},{"issue":"2","key":"2122_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12094-012-0926-8","volume":"15","author":"MD Delgado","year":"2013","unstructured":"Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Le\u00f3n J. MYC oncogene in myeloid neoplasias. Clinical & translational oncology: official publication of the. Federation Span Oncol Soc Natl Cancer Inst Mexico. 2013;15(2):87\u201394. https:\/\/doi.org\/10.1007\/s12094-012-0926-8.","journal-title":"Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"17","key":"2122_CR58","first-page":"6480","volume":"61","author":"S Schreiner","year":"2001","unstructured":"Schreiner S, Birke M, Garc\u00eda-Cu\u00e9llar MP, Zilles O, Greil J, Slany RK. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res. 2001;61(17):6480\u20136.","journal-title":"Cancer Res"},{"issue":"7","key":"2122_CR59","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2005-02-0734","volume":"106","author":"H Luo","year":"2005","unstructured":"Luo H, Li Q, O\u2019Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005;106(7):2452\u201361. https:\/\/doi.org\/10.1182\/blood-2005-02-0734.","journal-title":"Blood"},{"issue":"6","key":"2122_CR60","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1172\/jci39964","volume":"120","author":"Z Xiang","year":"2010","unstructured":"Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, Tomasson MH. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Investig. 2010;120(6):2109\u201318. https:\/\/doi.org\/10.1172\/jci39964.","journal-title":"J Clin Investig"},{"issue":"4","key":"2122_CR61","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","volume":"37","author":"K Basso","year":"2005","unstructured":"Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37(4):382\u201390. https:\/\/doi.org\/10.1038\/ng1532.","journal-title":"Nat Genet"},{"issue":"3","key":"2122_CR62","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.18632\/aging.203886","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie B, Li K, Zhang H, Lai G, Li D, Zhong X. Identification and validation of an immune-related gene pairs signature for three urologic cancers. Aging. 2022;14(3):1429\u201347. https:\/\/doi.org\/10.18632\/aging.203886.","journal-title":"Aging"},{"key":"2122_CR63","doi-asserted-by":"publisher","unstructured":"Zhang Z, Lai G, Sun L. Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II\/III Gliomas. Genes. 2022;13(10). https:\/\/doi.org\/10.3390\/genes13101810.","DOI":"10.3390\/genes13101810"},{"issue":"39","key":"2122_CR64","doi-asserted-by":"publisher","first-page":"e44767","DOI":"10.1097\/md.0000000000044767","volume":"104","author":"C Xu","year":"2025","unstructured":"Xu C, Qi H, Yang L, Jiang C. Identification and validation of immune-associated gene signatures for prognostic prediction in acute myeloid leukemia. Medicine. 2025;104(39):e44767. https:\/\/doi.org\/10.1097\/md.0000000000044767.","journal-title":"Medicine"},{"issue":"17","key":"2122_CR65","doi-asserted-by":"publisher","first-page":"e36624","DOI":"10.1016\/j.heliyon.2024.e36624","volume":"10","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhu H, Sheng Y, Cheng Z, Peng H. A novel prognostic model based on pyroptosis signature in AML. Heliyon. 2024;10(17):e36624. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36624.","journal-title":"Heliyon"},{"issue":"1","key":"2122_CR66","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1186\/s40001-025-03338-0","volume":"30","author":"D Zhang","year":"2025","unstructured":"Zhang D, Li G. Solute carrier-correlated gene signature in predicting the prognosis and immunity in patients with acute myeloid leukemia. Eur J Med Res. 2025;30(1):1107. https:\/\/doi.org\/10.1186\/s40001-025-03338-0.","journal-title":"Eur J Med Res"},{"issue":"2","key":"2122_CR67","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00204-024-03910-3","volume":"99","author":"C Zhang","year":"2025","unstructured":"Zhang C, Shi D, Lai G, Li K, Zhang Y, Li W, Zeng H, Yan Q, Zhong X, Xie B. A transcriptome-wide association study integrating multi-omics bioinformatics and Mendelian randomization reveals the prognostic value of ADAMDEC1 in colon cancer. Arch Toxicol. 2025;99(2):645\u201365. https:\/\/doi.org\/10.1007\/s00204-024-03910-3.","journal-title":"Arch Toxicol"},{"issue":"1","key":"2122_CR68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12672-024-01565-1","volume":"15","author":"F Yu","year":"2024","unstructured":"Yu F, Jiang H, Gu Y. Causal relationship between immune cells and acute myeloid leukemia: a two-sample Mendelian randomization study. Discover Oncol. 2024;15(1):675. https:\/\/doi.org\/10.1007\/s12672-024-01565-1.","journal-title":"Discover Oncol"},{"issue":"1","key":"2122_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41408-024-01168-7","volume":"14","author":"SA Beer","year":"2024","unstructured":"Beer SA, Went M, Hislop JM, Houlston R, Kaiser M. Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation. Blood cancer J. 2024;14(1):183. https:\/\/doi.org\/10.1038\/s41408-024-01168-7.","journal-title":"Blood cancer J"},{"issue":"10","key":"2122_CR70","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/2767-9764.Crc-24-0402","volume":"4","author":"G Jiang","year":"2024","unstructured":"Jiang G, Cao L, Wang Y, Li L, Wang Z, Zhao H, Qiu Y, Feng B. Causality between Telomere Length and the Risk of Hematologic Malignancies: A Bidirectional Mendelian Randomization Study. Cancer Res Commun. 2024;4(10):2815\u201322. https:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0402.","journal-title":"Cancer Res Commun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02122-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:02:27Z","timestamp":1774371747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02122-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2122"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02122-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of West China Hospital of Sichuan University, in accordance with the Declaration of Helsinki, as well as applicable national regulations on human subjects and genomic data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants or their authorized guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. This manuscript contains no individual person\u2019s data (including images, videos, or detailed case descriptions) that would require consent to publish.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"197"}}